Recent Updates
Recently added Catalysts

BMS-986490

Phase 1

Advanced Solid Tumors | Small molecule | Oncology |Bristol-Myers Squibb Company|Last Updated: Dec 15, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment360
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06730750A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsPHASE1 RECRUITING 360 — — Feb 12, 2025Dec 9, 2029Dec 15, 20256 United States, Australia +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of participnats with Adverse Events (AEs)
Up to 100 days following discontinuation of dosing
Number of participants with Serious AEs (SAEs)
Up to 100 days following discontinuation of dosing
Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteria
Up to 28 days after the first treatment of study intervention
Number of participants with AEs leading to discontinuation
Up to 100 days following discontinuation of dosing
Number of deaths
Up to 100 days following discontinuation of dosing
Secondary Endpoints
Area under the concentration-time curve in 1 dosing interval (AUC(TAU))
Approximately 30 Days after Cycle 30, Day 1 (1 Cycle = 21 Days)
Trough observed concentration (Ctrough)
Approximately 30 Days after Cycle 30, Day 1 (1 Cycle = 21 Days)
Maximum observed concentration (Cmax)
Approximately 30 Days after Cycle 30, Day 1 (1 Cycle = 21 Days)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part 1AEXPERIMENTAL -
Part 2A - Colorectal Cancer (CRC)EXPERIMENTAL -
Part 2A - Non-Small Cell Lung Cancer/Gastric Cancer (NSCLC/GC)EXPERIMENTAL -
Part 1BEXPERIMENTAL -
Part 2BEXPERIMENTAL -
Interventions
NameTypeDescription
BMS-986490DRUGSpecified dose on specified days.
BevacizumabDRUGSpecified dose on specified days.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: * Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1. * CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B: i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and...

Countries:United StatesAustraliaCanada
Unlock Eligibility Criteria
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06730750primaryCompletionDate: changed
LOWMay 24, 2026NCT06730750studyFirstPostDate: changed